Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.31 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.31 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.30 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.30 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3407428 | 0.90 | MLYCD (0.34) | MLYCDPDE3BPDE3AP2RY12 | |
| SCHEMBL3403346 | 0.88 | MLYCD (0.36) | MLYCDAGTR1AGTR2PDE3BPDE3A | |
| SCHEMBL3403716 | 0.88 | MLYCD (0.32) | MLYCDPDE3BPDE3AP2RY12 | |
| SCHEMBL3405756 | 0.88 | CYSLTR2 (0.34) | MLYCDCYSLTR2CYSLTR1PDE3BPDE3A | |
| SCHEMBL3403239 | 0.87 | MLYCD (0.35) | MLYCDAGTR1AGTR2PDE3BPDE3A | |
| SCHEMBL3406275 | 0.87 | MLYCD (0.36) | MLYCDPDE3BPDE3AP2RY12 | |
| SCHEMBL3406656 | 0.85 | MLYCD (0.43) | MLYCD | |
| SCHEMBL3406518 | 0.85 | POLB (0.34) | MLYCDPDE3BPDE3AP2RY12 | |
| SCHEMBL3403831 | 0.83 | NPC1 (0.34) | — | |
| SCHEMBL3402147 | 0.83 | MLYCD (0.39) | MLYCDCYSLTR2CYSLTR1PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370260-B1 | AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2010-11-24 | — | — | EP | claimed |
| US-20040092503-A1 | Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-05-13 | — | — | US | claimed |
| EP-1370260-A2 | AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-12-17 | — | — | EP | claimed |
| WO-2002066035-A2 | AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-08-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092503-A1 | Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators | ME1, ME3, ME2 | MLYCD 4/4885AGTR1 293/4885AGTR2 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.